Pharvaris

Pharvarians presented #deucrictibant data at the European Academy of Allergy and Clinical Immunology - EAACI Congress and the Eastern Allergy Conference this past weekend. We are grateful to the #HAE community for the continued #collaboration and support of #drugdevelopment. #TBT

The #EAACI2024 European Academy of Allergy and Clinical Immunology - EAACI in #Valencia was an amazing experience! I have had the privilege of participating in a global HAE advisory board, recording a video, co-authoring posters and oral presentations, and sharing experiences with friends and colleagues from around the world.  An incredible opportunity to meet friends again and continue exploring and learning the latest practices in #allergy & #immunology. Thank you everyone!!

Pharvaris recently presented data highlighting the unique #pharmacological and #clinical properties of #deucrictibant for the treatment and prevention of #HAE attacks at the European Academy of Allergy and Clinical Immunology - EAACI Congress, the Eastern Allergy Conference, and the International Drug Discovery Sciences & Technology (IDDST) Congress. Read more about the data presented here: https://lnkd.in/eNePsr_R

Many faces, one family. Pharvaris is a proud supporter of hae day :-) to raise #awareness of #hae #hereditaryangioedema. Today, we celebrate #HAEday along with organizations like HAE International (HAEi) and Hereditary Angioedema Association - HAEA.

The Pharvaris team is presenting at the 20th Annual Congress of International Drug Discovery Science and Technology (#IDDST); the 2024 Eastern Allergy Conference (#EAC); and the European Academy of Allergy and Clinical Immunology - EAACI (#EAACI) Congress 2024. Click here to find out more about our #clinical and #nonclinical presentations: https://lnkd.in/g6H2DEsf

This afternoon, Pharvaris reported our first quarter 2024 financial results and provided a business update. Read the full PR here: https://lnkd.in/giW4R_Hx Berndt Modig, Pharvaris' CEO, stated, "Pharvaris is executing from a position of financial and operational strength as we enroll in RAPIDe-3, our Phase 3 on-demand study of deucrictibant, and prepare for initiation of CHAPTER-3, our Phase 3 prophylactic study of deucrictibant. We believe deucrictibant has the potential to be the preferred therapeutic option for both the treatment and prevention of HAE attacks. Pharvaris continues to further build its team and infrastructure to support two late-stage clinical trials and prepare for the commercial launch of deucrictibant for people living with HAE.”

Pharvaris is hiring a #Global Head of #Quality. To support our primary programs aimed at bringing new, oral options to people living with hereditary angioedema (HAE), we have an opportunity for a highly driven Global Head of Quality to join and take #strategicdirection of our Quality department as the organization evolves. This newly created position will ensure that we continue to follow #FDA and international regulatory requirements for our Small Molecule Drug Substance (DS) and Drug Product (DP) as we continue down clinical pathways towards a potential commercial future. The Global Head of Quality will be based on the East Coast of the United States (Hybrid/Remote) and will be attached to our operations in the Boston, MA area. They will report to the VP, Regulatory Affairs & Quality. They will work closely with our existing Quality and Technical Operations teams to ensure that Quality is at the heart of everything we do. SaraBeth Hahn, PharmD, RPh For more information, please explore our careers website: https://lnkd.in/d3zgSkK

The Pharvaris team is onsite at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Meeting in Arlington, TX. Visit us at our booth and connect with our team Kenneth Robinson Amy DeWerth Wim Souverijns #HAE #deucrictibant #drugdevelopment

This afternoon, Pharvaris reported our fourth quarter and full year 2023 financial results and provided a business update. Highlights include enrollment in RAPIDe-3, scheduling an End-of-Phase 2 meetings to discuss development plan of deucrictibant for the prophylaxis of HAE attacks, strengthening the executive committee, and receipt of the UK Innovation Passport. #clinicaltrials #newhires #therapeuticinnovation Read the full press release here: https://lnkd.in/e2zGM6HB

Welcome, David Nassif, to the Pharvaris team! In the role of Chief Financial Officer, Mr. Nassif will be responsible for refining and implementing Pharvaris’ corporate #financialstrategy and activities including #financial #reporting and #operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial #management, #strategicplanning, #mergersandacquisitions, #investorrelations, #legal, and #capitalallocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies. Read the full press release here: https://lnkd.in/eRfP54vz